Comparative Pharmacology
Head-to-head clinical analysis: EXSEL versus MENTAX TC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXSEL versus MENTAX TC.
EXSEL vs MENTAX-TC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
1-2 mg orally once daily; maximum dose 2 mg/day.
Apply a thin layer to affected area once daily for 2-4 weeks.
None Documented
None Documented
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug.
Category C
Category C
Topical Antifungal
Topical Antifungal